24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
DataTech
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Biopharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
18:47
Group 11 strikes $20 million deal for second fund holdings, including Tipalti, Navan, and Sunbit
16:08
Investment in Israeli climate tech is shrinking at an alarming rate
14:30
Mekorot to allow small suppliers to sell it electricity
14:21
After losing 99% of its value, hospitality company Selina receives $20 million lifeline from Osprey Investments
More stories
Buzz
Most popular
Daily
Weekly
1
Tuition of terror: Qatari money flowed into U.S. universities - and now it's fueling violence
2
Tech titans line up: The leading companies ready for blockbuster IPOs in 2024
3
Fintech startup Pontera raises $60 million at $550 million valuation
4
Hackers extorting fintech unicorn Tipalti, threaten to leak data of clients Roblox and Twitch
5
Group 11 strikes $20 million deal for second fund holdings, including Tipalti, Navan, and Sunbit
More news
Biopharma
6 stories about Biopharma
Biopharma company Short Wave partnering in clinical trial for eating disorders with Sheba Fund
16.08.22
|
CTech
The trial will study the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa
SpliSense secures $28.5 million in funding to advance mRNA-altering pipeline for treatment of CF
13.05.21
|
Meir Orbach
The Israeli startup was founded by Prof. Batsheva Kerem, a renowned geneticist from the Hebrew University of Jerusalem, and its technology is based on her research
Israeli biopharma startup Omnix Medical awarded €10.8 million from EU to fight drug-resistant bacteria
26.01.21
|
Meir Orbach
The novel agents developed by Omnix are designed as an alternative to classical antibiotics
Nasdaq-Listed Biopharma Company Chiasma Raises $34.5 Million in Public Offering
09.04.19
|
CTech
Chiasma develops octreotide capsules for the treatment of acromegaly, a rare, chronic disease typically caused by a benign tumor of the pituitary gland
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
24.07.18
|
Lilach Baumer
The Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market
RedHill's Public Offering Spooks Investors, Sends Stock Down
09.11.17
|
Dror Reich
The Nasdaq-listed biopharmaceutical company priced its shares at $5.5 per American Depositary Share, a third of its 2015 public offering price, and dropped nearly 30% by Wednesday market close
Please ensure Javascript is enabled for purposes of
website accessibility